RayKnowChina Research Map
Shortlist

RecruitingLymphomaPhase 2

Registered title, quoted from ClinicalTrials.gov

Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma

An open trial on lymphoma, registered on ClinicalTrials.gov. Led by Sun Yat-sen University Cancer Center; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead (inferred)Sun Yat-sen University Cancer Center中山大学肿瘤防治中心GuangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06846489, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Histologically confirmed CD20+ mantle cell lymphoma.

    Inclusion criterion 2

  3. Received any investigational drug within 30 days (or 5 half-lives, whichever is shorter) prior to the first dose of the investigational drug.

    Exclusion criterion 5

    Underwent major surgery within 30 days prior to the first dose of the investigational drug. Note: If the participant has undergone major surgery, they must be fully recovered from any toxicity and/or complications related to the surgery before the first dose.

    Exclusion criterion 6

    History of stroke or intracranial hemorrhage within 6 months prior to the first dose of the investigational drug.

    Exclusion criterion 14

  4. ECOG performance status 0-2, no deterioration >2 weeks before baseline or first dose.

    Inclusion criterion 5

  5. A history of malignancy that could affect protocol adherence or interpretation of results, except for: a. Basal cell carcinoma, squamous cell carcinoma of the skin, cervical carcinoma in situ, or prostate carcinoma in situ treated curatively at any time before the study. b. Other cancers that were treated surgically and/or with radiation, with no disease for ≥3 years without further treatment.

    Exclusion criterion 7

    Known HIV infection.

    Exclusion criterion 11

  6. Pregnancy or breastfeeding.

    Exclusion criterion 18

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06846489, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Key inclusion Criteria:

  • Age ≥18 years.
  • Histologically confirmed CD20+ mantle cell lymphoma.
  • No prior anti-lymphoma treatment.
  • Ann Arbor stage II-IV.
  • ECOG performance status 0-2, no deterioration >2 weeks before baseline or first dose.
  • Younger subjects (<65) must meet:
  • Low to intermediate risk sMIPI (0-5)
  • Ki67 < 50%
  • No TP53 mutation (NGS)
  • Lesion diameter ≤5 cm
  • Non-blastoid, polymorphic disease
  • At least one assessable lesion per Lugano 2014 criteria.
  • Adequate organ and bone marrow function during screening.
  • Female subjects must use contraception as per local regulations.
  • Male subjects must agree to avoid sperm donation during the study and for 12 months post-rituximab.
  • Willing to undergo all required assessments and procedures, including swallowing capsules/tablets.
  • Able to understand the study's purpose and risks, and provide signed informed consent with authorization for the use of personal health information.

Key exclusion Criteria:

  • Participants with tumor burden reduction prior to stem cell transplantation.
  • History of active lymphoma central nervous system (CNS) involvement, leptomeningeal disease, or spinal cord compression.
  • Any disease evidence deemed by the investigator to be detrimental to the patient's participation or likely to affect protocol adherence (e.g., severe or uncontrolled systemic disease, including uncontrolled hypertension or kidney transplant).
  • History of progressive multifocal leukoencephalopathy (PML) or current diagnosis of PML.
  • Received any investigational drug within 30 days (or 5 half-lives, whichever is shorter) prior to the first dose of the investigational drug.
  • Underwent major surgery within 30 days prior to the first dose of the investigational drug. Note: If the participant has undergone major surgery, they must be fully recovered from any toxicity and/or complications related to the surgery before the first dose.
  • A history of malignancy that could affect protocol adherence or interpretation of results, except for: a. Basal cell carcinoma, squamous cell carcinoma of the skin, cervical carcinoma in situ, or prostate carcinoma in situ treated curatively at any time before the study. b. Other cancers that were treated surgically and/or with radiation, with no disease for ≥3 years without further treatment.
  • Significant cardiovascular disease, such as symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months before screening, or any NYHA Class 3 or 4 heart disease during screening. Note:Participants with well-controlled, asymptomatic atrial fibrillation are allowed.
  • Refractory nausea and vomiting, difficulty swallowing formulations, or malabsorption syndrome; chronic gastrointestinal disease, gastric bypass, or weight-loss surgery (e.g., Roux-en-Y); partial or complete bowel obstruction, or previous major intestinal surgery that may interfere with the absorption, distribution, metabolism, or elimination of the investigational drug.
  • Received a live-virus vaccine within 28 days prior to the first dose of the investigational drug.
  • Known HIV infection.
  • Any active major infection (e.g., bacterial, viral, or fungal, including subjects with positive CMV DNA PCR).
  • Serologic evidence of active hepatitis B or C infection.
  • History of stroke or intracranial hemorrhage within 6 months prior to the first dose of the investigational drug.
  • History of bleeding disorders (e.g., hemophilia, Von Willebrand disease).
  • Requires or is receiving anticoagulation therapy with warfarin or equivalent vitamin K antagonists.
  • Requires strong CYP3A inhibitors or inducers. The use of strong CYP3A inhibitors within 1 week or strong CYP3A inducers within 3 weeks before the first dose of the investigational drug is prohibited.
  • Pregnancy or breastfeeding.
  • Participation in another therapeutic clinical trial.
  • Requires proton pump inhibitor therapy (e.g., omeprazole, esomeprazole, lansoprazole, dexlansoprazole, rabeprazole, or pantoprazole).
  • Currently has a life-threatening disease, medical condition, or organ system dysfunction that, in the investigator's judgment, may compromise the participant's safety or place the study at risk.

Quoted from ClinicalTrials.gov, NCT06846489, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06846489, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06846489